Our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells that improve cell-based assay outcomes. We develop and scalably manufacture human induced pluripotent stem (iPS) cell-derived cardiac and neural platforms for drug discovery and development. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. We also collaborate with drug discovery organizations to test their compounds with our in-house screening capabilities, create new cell-based models, and operationalize their human iPS cells at large scale for high throughput screening.
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity. StemoniX microBrain® products in high density formats are physiologically relevant with biology, activity, functional maturity that mimic native human brain tissue. Available pre-plated to simplify your workflow, microHeart and microBrain are delivered in ambient conditions and ready for assay use soon after delivery.
With leading-edge iPSC technologies, we are helping global institutions bring the most promising medicines to patients. Contact us at info@stemonix.com to discuss how StemoniX products and services can accelerate your discoveries.
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity. StemoniX microBrain® products in high density formats are physiologically relevant with biology, activity, functional maturity that mimic native human brain tissue. Available pre-plated to simplify your workflow, microHeart and microBrain are delivered in ambient conditions and ready for assay use soon after delivery.
With leading-edge iPSC technologies, we are helping global institutions bring the most promising medicines to patients. Contact us at info@stemonix.com to discuss how StemoniX products and services can accelerate your discoveries.
Location: United States, Minnesota, Maple Grove
Employees: 11-50
Total raised: $14.4M
Founded date: 2014
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.03.2019 | Series B | $14.4M | - |
Mentions in press and media 7
| Date | Title | Description |
| 12.01.2021 | StemoniX to Participate in Biotech Showcase(TM) Digital 2021 | Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi... |
| 14.08.2020 | Canada’s Atomwise secures 163M CAD in Series B funding | The AI-driven drug discovery platform was founded in 2012 by Abraham Heifets, Alexander Levy and Dr. Izhar Wallach and was earlier known as Chematria. It was initially a part of University of Toronto’s incubator before associating with Y Co... |
| 01.03.2019 | Term Sheet — Friday, March 1 | PAYING UP FOR CYBERSECURITY Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop The deal is being made through KKR’s $711 million Next Generation Technology Growth Fund, which target... |
| 01.03.2019 | Daily funding roundup - March 1st, 2019 | Odaseva raised $11.7M; StemoniX raised $14.4M; Bandier raised $34.4M; Jet Edge raised $60M Odaseva: Odaseva develops cloud-based software solutions that enable salesforce customers to secure their data and industrialize their centers of exc... |
| 28.02.2019 | StemoniX Secures $14.4M in Series B Funding | StemoniX Inc., a Maple Grove, Minn.-based biotech company, secured $14.4m USD in Series B funding. The round was led by Brightstone Venture Capital with participation from initial investors Crescent Ridge Partners and SEED San Diego, as wel... |
| 28.02.2019 | StemoniX Nabs $14.4M Series B | MAPLE GROVE, MN, StemoniX announced today that it has secured $14.4 million in Series B funding. >> Click here for more funding data on StemoniX >> To export StemoniX funding data to PDF and Excel, click here StemoniX®, ... |
| 04.06.2018 | Digital Manufacturing and Logistics | Legacy Manufacturing Hubs Manufacturing and farming ecosystems in the US and around the world have developed around a combination of the following ingredients: raw materials (minerals, crops), energy (electric, hydro, wind, solar), logistic... |